Loading
A phase 3 trial testing TARA-002 in bladder & urothelial cancer, now recruiting.
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer is a phase 3 interventional study registered as NCT07480356, led by Protara Therapeutics, and recruiting on the registry. Official title: A Phase 3, Randomised Study to Evaluate the Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-Grade Non-Muscle Invasive Bladder Cancer. Planned enrolment is 284 participants (estimated). The study started in 2026-05-29 and primary completion is expected in 2028-04. No results have been posted on ClinicalTrials.gov.
Shares TARA-002, Protara Therapeutics, Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.